Equities

Crescita Therapeutics Inc

CTX:TOR

Crescita Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)0.44
  • Today's Change0.005 / 1.15%
  • Shares traded10.52k
  • 1 Year change-32.31%
  • Beta1.6961
Data delayed at least 15 minutes, as of Jun 25 2024 19:18 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. It also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER and Obagi Medical in Canada. The Licensing and Royalties segment engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. Manufacturing and Services segment engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization infrastructure, and sales of product development services.

  • Revenue in CAD (TTM)17.92m
  • Net income in CAD-2.34m
  • Incorporated2016
  • Employees78.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Rakovina Therapeutics Inc0.00-2.72m7.01m----2.38-----0.039-0.0390.000.0420.00-------53.46---56.12-------------16.520.3151------6.39------
XORTX Therapeutics Inc0.00-4.57m8.14m3.00--2.39-----1.92-1.920.001.170.00-------42.59-35.42-45.30-40.37------------0.0056------72.04--7.91--
Therma Bright Inc25.80k-2.88m8.41m----3.44--326.06-0.0115-0.01150.00010.00580.00760.00230.115---84.40-220.66-165.23-444.5798.45---11,152.48-10,853.160.0447-184.520.0411---82.8611.1335.93--40.15--
Crescita Therapeutics Inc17.92m-2.34m8.47m78.00--0.4685--0.473-0.1162-0.11620.89270.92850.69031.504.62---9.01-0.2457-11.40-0.305956.0363.41-13.06-0.35182.60--0.0594---25.521.05-330.39---1.58--
Khiron Life Sciences Corp16.14m-30.66m9.30m310.00------0.5761-0.1674-0.16740.0850.12480.30781.333.9052,055.68-58.47---69.10--19.51---190.00--0.9133--0.0864--59.60---37.81------
Delivra Health Brands Inc12.11m-711.00k9.38m----2.6415.480.7745-0.0026-0.00260.04260.01141.232.507.19---7.25-45.81-14.01-58.3455.9337.95-5.87-289.551.500.00910.3613--20.3068.2697.37---56.72--
Data as of Jun 25 2024. Currency figures normalised to Crescita Therapeutics Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.